CONTENTS

Chapter 1 General Introduction 9

Chapter 2 HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review 31

Chapter 3 Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V 57

Chapter 4 Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines 75

Chapter 5 Cellular resistance to HIV protease inhibitor lopinavir in a human T cell line (CEM) is associated with ABCG1 downregulation and decreased apoptosis capacity 93

Chapter 6 The lopinavir/ritonavir-associated rise in lipids is not related to the lopinavir or ritonavir plasma concentration 115

Chapter 7 General discussion
Where we stand with HIV protease inhibitors: a SWOT analysis 131

Chapter 8 Summary 151

Addendum Dutch summary - Nederlandse samenvatting 158
Acknowledgements - Dankwoord 162
Curriculum vitae 165
List of publications 166